Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives $117.82 Consensus Price Target from Brokerages

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) has received an average recommendation of “Moderate Buy” from the fourteen analysts that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $117.8182.

Several brokerages have recently issued reports on DNTH. Raymond James Financial restated a “strong-buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Wedbush upped their price objective on Dianthus Therapeutics from $103.00 to $105.00 and gave the company an “outperform” rating in a research note on Wednesday, May 6th. Oppenheimer increased their price objective on Dianthus Therapeutics to $145.00 and gave the company an “outperform” rating in a report on Monday, March 9th. Stifel Nicolaus set a $120.00 target price on Dianthus Therapeutics in a research report on Monday, March 9th. Finally, Guggenheim restated a “buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th.

Dianthus Therapeutics Stock Performance

Shares of NASDAQ:DNTH opened at $94.34 on Tuesday. The company’s 50-day moving average is $86.70 and its 200 day moving average is $69.82. The company has a market capitalization of $5.16 billion, a P/E ratio of -22.84 and a beta of 1.20. Dianthus Therapeutics has a fifty-two week low of $17.88 and a fifty-two week high of $98.70.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.85) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.07) by $0.22. The business had revenue of $0.46 million during the quarter, compared to the consensus estimate of $0.40 million. Dianthus Therapeutics had a negative net margin of 12,998.50% and a negative return on equity of 27.30%. As a group, research analysts predict that Dianthus Therapeutics will post -3.82 earnings per share for the current year.

Insider Transactions at Dianthus Therapeutics

In other news, EVP Simrat Randhawa sold 26,530 shares of the stock in a transaction on Monday, June 1st. The stock was sold at an average price of $90.62, for a total transaction of $2,404,148.60. Following the completion of the transaction, the executive vice president owned 4,000 shares in the company, valued at approximately $362,480. This represents a 86.90% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Adam M. Veness sold 30,000 shares of Dianthus Therapeutics stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $80.80, for a total value of $2,424,000.00. Following the completion of the sale, the senior vice president directly owned 30,000 shares of the company’s stock, valued at approximately $2,424,000. This trade represents a 50.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 64,754 shares of company stock worth $5,566,993. 3.02% of the stock is owned by company insiders.

Hedge Funds Weigh In On Dianthus Therapeutics

Large investors have recently modified their holdings of the business. Seven Fleet Capital Management LP raised its position in shares of Dianthus Therapeutics by 451.6% in the first quarter. Seven Fleet Capital Management LP now owns 80,809 shares of the company’s stock valued at $6,781,000 after purchasing an additional 66,158 shares during the period. DV Trading LLC bought a new position in Dianthus Therapeutics in the 1st quarter worth approximately $2,228,000. Glenmede Trust Co. NA grew its stake in Dianthus Therapeutics by 96.5% in the 1st quarter. Glenmede Trust Co. NA now owns 12,470 shares of the company’s stock valued at $1,046,000 after buying an additional 6,125 shares in the last quarter. Stempoint Capital LP grew its stake in Dianthus Therapeutics by 7.8% in the 1st quarter. Stempoint Capital LP now owns 85,502 shares of the company’s stock valued at $7,175,000 after buying an additional 6,218 shares in the last quarter. Finally, Janus Henderson Group PLC grew its stake in Dianthus Therapeutics by 96.4% in the 1st quarter. Janus Henderson Group PLC now owns 16,500 shares of the company’s stock valued at $1,384,000 after buying an additional 8,100 shares in the last quarter. Hedge funds and other institutional investors own 47.53% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.